Page last updated: 2024-11-04

risedronic acid and Sjogren's Syndrome

risedronic acid has been researched along with Sjogren's Syndrome in 1 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Sjogren's Syndrome: Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.

Research Excerpts

ExcerptRelevanceReference
"By 24 months, renal tubular acidosis was improved and the bone density had normalized."1.39Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. ( Hirata, S; Inokuchi, N; Mori, H; Okada, Y; Saito, K; Tanaka, Y; Yamamoto, S, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yamamoto, S1
Okada, Y1
Mori, H1
Hirata, S1
Saito, K1
Inokuchi, N1
Tanaka, Y1

Other Studies

1 other study available for risedronic acid and Sjogren's Syndrome

ArticleYear
Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome.
    Modern rheumatology, 2013, Volume: 23, Issue:2

    Topics: Acidosis, Renal Tubular; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid

2013